Wednesday, April 2, 2014

The Buzz at #PCTUS: Top Tweets From This Week

This post was written by Mike Madarasz of the Institute for International Research. You can follow him on Twitter at @MikeMadarasz.

Over the course of the last two and half days, there was a great deal of discussion worthy of being shared.  Social media helps to amplify this thought leadership and we'd like to thank everyone for their tweets this week.  Out of nearly 1,000 tweets between 233 participants, we were able to pick six that warrant your attention.  
Big data (AKA "real world data") was a big theme this year.  No surprise there. The fact that it is such a buzzword has diluted some of it's meaning over time.  This week we were reminded again and again that the return on big data comes from the insight it provides and not just the metrics in and of themselves. 

Patient centricity was another topic that was top of mind with many leaders this week.  This idea was one that was met with heavy approval from attendees.  The message here: Clinical trials revolve around patients and in order to be successful, it is the patients that need to be involved.   

Jerry is almost certainly not the only one suffering from some degree of big data "fatigue".  The value is there but the method for extracting that value appears to be something that needs to be addressed on a case-by-case basis.

Another one of everyone's favorite words: Innovate.  That said, this tweet warranted a spot on our list as a gentle reminder.  Thanks for the tweet, MaryAnne.

This was a big takeaway from Roni Zeiger's discussion on patient centricity on day two.  Roni spoke passionately one open lines of communication between doctors and patients as well as giving patients a say in clinical trials.

Deidre BeVard challenged the delegates of the conference to be more social.  There is a lot to be shared and much to be learned at conferences such as Partnerships in Clinical Trials.  Social media provides a medium to expedite this learning process.  That said, we can certainly appreciate where Deidre is coming from.  

No comments: